Sonoma Pharmaceuticals (SNOA) Stock: Buy, Sell, or Hold?
SNOA - Sonoma Pharmaceuticals, Inc. Common Stock
$1.31
-0.01 (-0.38%)
âŧ
5d:
-1.14%
30d:
-4.74%
90d:
+18.64%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 03, 2026
Get Alerted When SNOA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: SNOA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: SNOA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: SNOA is currently trading at $1.30, which is considered fair relative to its 30-day fair value range of $1.26 to $1.37.
Technical Outlook: Technically, SNOA is showing sideways momentum. Immediate support is located at $1.26, while resistance sits at $1.37.
Market Sentiment: SNOA scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.00 (+819.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SNOA is showing sideways momentum. Immediate support is located at $1.26, while resistance sits at $1.37.
Market Sentiment: SNOA scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.00 (+819.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.26 -
$1.37
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (30/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 819.5% below Wall St target ($12.00)
- WARNING: Composite score 46/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.26 -
$1.37
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.26
Resistance Level
$1.37
Current Trend
Sideways
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.33
Wall Street Target
$12.00
(+819.5%)
Revenue Growth (YoY)
59.6%
Profit Margin
-10.3%
Share & Embed Analysis
Last updated: September 12, 2026 10:55 AM ET
Data refreshes hourly during market hours. Next update: 11:55 AM
Data refreshes hourly during market hours. Next update: 11:55 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SNOA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$212 | 60 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 70 BUY |
|
INDV
Indivior PLC Ordinary ShâĻ |
STRONG BUY
7 analysts |
$49 | 69 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 46 HOLD |
|
UTHR
United Therapeutics CorpâĻ |
STRONG BUY
15 analysts |
$664 | 47 HOLD |
